Although the expression of PD-L1 is a predictive biomarker for the result of immunotherapy in patients with multiple tumor types, the therapeutic effect of targeting PD-L1 is unsatisfactory (21, 32, 33). This evidence concerns the gene CD274 and neoplasm.